• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Castle Biosciences, Inc. - Common stock (NQ: CSTL )

    27.53 +0.44 (+1.62%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 382,571
    Open 26.58
    Bid (Size) 27.50 (1)
    Ask (Size) 30.69 (1)
    Prev. Close 27.09
    Today's Range 26.58 - 27.99
    52wk Range 16.96 - 35.84
    Shares Outstanding 25,167,365
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Castle Biosciences Inc.
    Via Business Wire
    Independent Systematic Review and Meta-Analysis Attests to the Significant Risk Stratification Provided by Castle Biosciences’ DecisionDx®-Melanoma Test, Contributing to Personalized Management of Patients with Melanoma
    From Castle Biosciences Inc.
    Via Business Wire

    Performance

    YTD
    +25.36%
    +25.36%
    1 Month
    -7.65%
    -7.65%
    3 Month
    -8.14%
    -8.14%
    6 Month
    +24.12%
    +24.12%
    1 Year
    +25.54%
    +25.54%

    More News

    Read More
    The Analyst Landscape: 4 Takes On Castle Biosciences
    Via Benzinga
    Sotera Health Stock Earns 91 RS Rating
    Via Investor's Business Daily
    Guardant Health Stock Sees RS Rating Jump To 83
    Via Investor's Business Daily
    Castle Biosciences to Present at the Piper Sandler 36th Annual Healthcare Conference
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fourth Consecutive Year
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Present New Data Highlighting the Clinical Performance of DecisionDx®-Melanoma and MyPath® Melanoma at the American Society of Dermatopathology 61st Annual Meeting
    From Castle Biosciences, Inc.
    Via Business Wire
    Castle Biosciences Surpasses 25,000 Test Reports Delivered for its TissueCypher® Barrett’s Esophagus Test
    From Castle Biosciences Inc.
    Via Business Wire
    Use of Castle Biosciences’ DecisionDx®-Melanoma Test Significantly Reduces Unnecessary SLNB Procedures, Latest Findings from Prospective, Multicenter DECIDE Study Presented at Dermato-Onco2024
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Reports Third Quarter 2024 Results
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher® Test to Significantly Reduce Healthcare Costs Associated with the Management of Barrett’s Esophagus Patients
    From Castle Biosciences Inc.
    Via Business Wire
    Momentum Has Narrowed Again, Significantly
    Via Talk Markets
    Castle Biosciences to Participate in Upcoming Investor Conferences
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Presents New Data at ASDS from Prospective, Multicenter CONNECTION Study Supporting Use of DecisionDx®-Melanoma to Guide SLNB Decisions in T1a Tumors with High-Risk Features and T1b Tumors
    From Castle Biosciences Inc.
    Via Business Wire
    Recent Publications Affirm the Value of Gene Expression Profile Testing in Guiding a Definitive Diagnosis and Clinical Decision-Making in Melanocytic Lesions of Uncertain Malignant Potential
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Release Third Quarter 2024 Financial Results and Host Conference Call on Monday, Nov. 4, 2024
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences to Support the 71st Annual Montagna Symposium on the Biology of the Skin
    From Castle Biosciences Inc.
    Via Business Wire
    New Prospective, Multicenter Study Presented at SMR Demonstrates Castle Biosciences’ DecisionDx®-Melanoma Test Provides Significant Risk Prediction for Patients with Cutaneous Melanoma, Adding Value to Current Stage-Based Treatment Pathway Decisions
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences Hosts Groundbreaking Ceremony at Site of New Corporate Headquarters in Friendswood, Texas
    From Castle Biosciences Inc.
    Via Business Wire
    New Data at ASTRO 2024 Shows Castle Biosciences’ DecisionDx®-SCC Test Provides More Precise Risk Stratification Than BWH Staging Alone to Guide Intensified Treatment for Immune Suppressed Patients with High-Risk Cutaneous Squamous Cell Carcinoma
    From Castle Biosciences Inc.
    Via Business Wire
    New Data at AFS 2024 Demonstrates the Strength of Castle Biosciences’ TissueCypher® Test in Independently Predicting Risk of Developing Esophageal Cancer, Guiding Risk-Aligned Management Decisions for Patients with Barrett’s Esophagus
    From Castle Biosciences Inc.
    Via Business Wire
    Castle Biosciences’ Chief Operating Officer Kristen Oelschlager Named Arizona Bioscience Leader of the Year
    From Castle Biosciences Inc.
    Via Business Wire
    DecisionDx®-Melanoma Can Identify Melanoma Patients with Low Risk of Sentinel Lymph Node Positivity Who May Safely Forego Biopsy Surgery, New Independent Study Affirms
    From Castle Biosciences Inc.
    Via Business Wire
    Study Confirms the Ability of Castle Biosciences' DecisionDx®-SCC Test to Predict Likelihood of Benefit from Adjuvant Radiation Therapy in Patients with High-Risk Cutaneous Squamous Cell Carcinoma
    From Castle Biosciences Inc.
    Via Business Wire
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.